Holen Sie sich die Stockscreener-App
24.75
0.61%
0.15
Handel nachbörslich:
24.75
Schlusskurs vom Vortag:
$24.60
Offen:
$24.52
24-Stunden-Volumen:
189.57K
Relative Volume:
1.25
Marktkapitalisierung:
$680.65M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-69.47M
KGV:
-4.4218
EPS:
-5.5973
Netto-Cashflow:
$-73.92M
1W Leistung:
+8.70%
1M Leistung:
-2.10%
6M Leistung:
+13.22%
1J Leistung:
+0.00%
1-Tages-Spanne:
$23.64
$25.46
1-Wochen-Bereich:
$21.98
$25.46
52-Wochen-Spanne:
$14.42
$38.93
Lenz Therapeutics Inc Stock (LENZ) Company Profile
Firmenname
Lenz Therapeutics Inc
Sektor
Branche
Telefon
858-925-7000
Adresse
201 LOMAS SANTA FE DRIVE, SUITE 300, SOLANA BEACH
Vergleichen Sie LENZ mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
LENZ
Lenz Therapeutics Inc
|
24.75 | 680.65M | 0 | -69.47M | -73.92M | -5.5973 |
|
VRTX
Vertex Pharmaceuticals Inc
|
502.92 | 129.14B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
680.61 | 74.41B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
581.21 | 35.31B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
241.75 | 31.30B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
254.57 | 27.35B | 3.32B | -860.46M | -1.04B | -8.32 |
Lenz Therapeutics Inc Stock (LENZ) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-09-27 | Eingeleitet | Raymond James | Outperform |
| 2024-08-12 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-04-15 | Eingeleitet | Leerink Partners | Outperform |
| 2024-04-15 | Eingeleitet | William Blair | Outperform |
| 2024-04-10 | Eingeleitet | Citigroup | Buy |
| 2024-03-27 | Eingeleitet | Piper Sandler | Overweight |
| 2023-02-23 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2023-02-23 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2023-02-23 | Herabstufung | Cowen | Outperform → Market Perform |
| 2023-01-25 | Herabstufung | BTIG Research | Buy → Neutral |
| 2023-01-18 | Herabstufung | BofA Securities | Buy → Neutral |
| 2023-01-06 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2023-01-06 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2022-09-15 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2022-06-17 | Eingeleitet | BMO Capital Markets | Outperform |
| 2022-04-14 | Eingeleitet | BTIG Research | Buy |
| 2022-03-22 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2022-02-18 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2021-07-20 | Eingeleitet | Morgan Stanley | Overweight |
| 2021-07-20 | Eingeleitet | SVB Leerink | Outperform |
Alle ansehen
Lenz Therapeutics Inc Aktie (LENZ) Neueste Nachrichten
LENZ Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Highlights on March 19, 2025 - The Manila Times
LENZ Therapeutics Q4 Earnings: Key Updates Coming on Presbyopia Eye Drops - StockTitan
Rhumbline Advisers Boosts Stock Position in LENZ Therapeutics, Inc. (NASDAQ:LENZ) - Defense World
LENZ Therapeutics to Host Commercial Day on April 15, 2025 - The Manila Times
Will LENZ's Presbyopia Eye Drop Disrupt the Vision Care Market? Commercial Strategy Reveal Coming - StockTitan
Insiders Enjoy US$227k Return After Buying LENZ Therapeutics Stock - Simply Wall St
LENZ Therapeutics to Participate in Upcoming Investor Conferences - The Manila Times
LENZ Therapeutics to Present at Upcoming Investor Conferences in March 2025 - Nasdaq
Can LENZ's Novel Presbyopia Treatment Disrupt the $8B Eye Care Market? Key Investor Presentations Coming - StockTitan
Myopia And Presbyopia Eye Drops Market Future Business - openPR
LENZ Therapeutics (LENZ) to Release Quarterly Earnings on Wednesday - Defense World
LENZ Therapeutics Insiders Placed Bullish Bets Worth US$551.1k - Yahoo Finance UK
Citi maintains Buy on LENZ Therapeutics, target at $44 By Investing.com - Investing.com Canada
Citi maintains Buy on LENZ Therapeutics, target at $44 - Investing.com
Mirae Asset Global Investments Co. Ltd. Makes New Investment in ArriVent BioPharma, Inc. (NASDAQ:AVBP) - Defense World
916 Shares in LENZ Therapeutics, Inc. (NASDAQ:LENZ) Acquired by Mirae Asset Global Investments Co. Ltd. - Defense World
LENZ Therapeutics (NASDAQ:LENZ) Shares Down 4.7%Should You Sell? - MarketBeat
LENZ Therapeutics, Inc. (NASDAQ:LENZ) Shares Acquired by SG Americas Securities LLC - Defense World
The Presbyopia Market Size to Reach USD 2,513.0 Million by 2035, Impelled by Technological Advancements in Diagnostic Tools - BioSpace
LENZ Therapeutics, Inc. (NASDAQ:LENZ) Receives Consensus Rating of "Buy" from Analysts - MarketBeat
LENZ Therapeutics, Inc. (NASDAQ:LENZ) Receives $35.40 Average Target Price from Brokerages - Defense World
LENZ Therapeutics (NASDAQ:LENZ) Trading 8% HigherWhat's Next? - MarketBeat
Research Analysts Set Expectations for LENZ FY2025 Earnings - MarketBeat
LENZ Therapeutics (NASDAQ:LENZ) Trading Down 5.1%What's Next? - MarketBeat
LENZ Therapeutics (LENZ) to Release Earnings on Wednesday - MarketBeat
Leerink Partnrs Has Pessimistic View of LENZ FY2025 Earnings - Defense World
More Heart, Less Skin: US FDA’s 2025 Novel Approvals Should Reflect Pipeline Shifts - News & Insights
Yankuang Energy Group Company Limited (OTCMKTS:YZCAY) Sees Large Decrease in Short Interest - Defense World
Myopia Pipeline 2024: Detailed Clinical Trials - openPR
LENZ Therapeutics (LENZ) Expected to Announce Earnings on Wednesday - Defense World
Barclays PLC Sells 1,835 Shares of Grupo Financiero Galicia S.A. (NASDAQ:GGAL) - Defense World
Presbyopia Market on Track for Major Expansion by 2034, According to DelveInsight - EIN News
LENZ Therapeutics, Inc. (NASDAQ:LENZ) Sees Significant Increase in Short Interest - Defense World
Lincoln Electric Holdings, Inc. (NASDAQ:LECO) Short Interest Down 5.0% in December - Defense World
LifeVantage Co. (NASDAQ:LFVN) Short Interest Down 5.4% in December - Defense World
Lifecore Biomedical, Inc. (NASDAQ:LFCR) Sees Significant Increase in Short Interest - Defense World
Morgan Stanley Cuts U.S. Bancorp (NYSE:USB) Price Target to $59.00 - Defense World
Short Interest in LENZ Therapeutics, Inc. (NASDAQ:LENZ) Expands By 11.9% - MarketBeat
Barclays PLC Has $391,000 Stake in LENZ Therapeutics, Inc. (NASDAQ:LENZ) - Defense World
Barclays PLC Buys 12,051 Shares of LENZ Therapeutics, Inc. (NASDAQ:LENZ) - MarketBeat
LENZ Therapeutics (NASDAQ:LENZ) Trading Down 5%Time to Sell? - MarketBeat
Trio-Tech International (NYSE:TRT) Coverage Initiated by Analysts at StockNews.com - Defense World
Harbor Capital Advisors Inc. Buys Shares of 43,989 LENZ Therapeutics, Inc. (NASDAQ:LENZ) - MarketBeat
Brokerages Set LENZ Therapeutics, Inc. (NASDAQ:LENZ) PT at $35.40 - Defense World
Jane Street Group LLC Acquires Shares of 12,027 LENZ Therapeutics, Inc. (NASDAQ:LENZ) - Defense World
LENZ Therapeutics (NASDAQ:LENZ) Shares Down 8.9%Here's What Happened - MarketBeat
Intellia stock hurts gene editing after layoffs (NTLA:NASDAQ) - Seeking Alpha
Finanzdaten der Lenz Therapeutics Inc-Aktie (LENZ)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.39%
0.55%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):